Quantcast

Latest Bioethics Stories

2014-07-29 08:33:38

NEW YORK, July 29, 2014 /PRNewswire/ -- Recently unveiled at the annual American Society of Clinical Psychopharmacology conference in Hollywood, FL, a new randomized, double-blinded, placebo-controlled human clinical trial conducted by The Brain Institute, at the University of Utah, found that adolescent males experienced increased motor speed and attention after supplementation of citicoline. The trial involved 75 adolescent males over a 28-day period in which the citicoline, a known...

2014-07-24 08:34:04

Expanding bio-risk management support for federal, state and institutional laboratories PRINCETON, N.J., July 24, 2014 /PRNewswire/ -- WIRB-Copernicus Group(®) ("WCG")(TM), the world's largest provider of regulatory and ethical review services for clinical research, announced today that it has acquired Alliance Biosciences. Formerly a division of Richmond, VA-based Alliance Engineering, Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United...

2014-07-21 10:19:04

North Shore-Long Island Jewish (LIJ) Health System The brain network measures placebo effects in Parkinson's disease patients Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation. Parkinson's disease is the second most common neurodegenerative disease in the...

2014-07-18 08:23:13

BASEL, Switzerland, July 18, 2014 /PRNewswire/ -- The Basel Declaration presented the Award for Education in Animal Research for the third consecutive year. The award winner, Vladimir Sergeevich Popov from the Moscow State University, will attend a 1-week course at Zuerich University for research with animals according to the rules of the 3Rs (Replace, Reduce, Refine). As head of the animal research laboratory at the Moscow State University, Popov has been given the task of...

2014-07-14 23:03:17

Dr. Carol Isaacson Barash is leading a provocative panel in discussing “Cluster Innovations in Personalized Medicine” at the CONVERGE: Innovation Meets Health Care conference on July 15, 2014. Dr. Barash and fellow panelists will discuss the confluence of innovations that are converging to advance the pace of personalized medicine. Boston, MA (PRWEB) July 14, 2014 Dr. Carol Isaacson Barash is leading a provocative panel in discussing “Cluster Innovations in Personalized Medicine”...

2014-07-14 08:27:24

HAMILTON, N.J., July 14, 2014 /PRNewswire/ -- Invivotek L.L.C., a member of the Genesis Biotechnology Group, LLC is pleased to announce that its animal research facility was awarded full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). AAALAC promotes the humane treatment of animals in science worldwide through voluntary accreditation and assessment programs. AAALAC recognizes the highest standards for animal...

2014-06-30 23:04:31

NutraGenesis announces a recent study published in the peer reviewed Journal of Clinical Psychiatry, the multi-patented, GRAS-affirmed, standardized Ashwagandha root and leaf extract, Sensoril®, was shown to improve several areas of cognitive effect in subjects with bipolar disorder. Brattleboro, VT (PRWEB) June 30, 2014 In a recent study published in the peer reviewed Journal of Clinical Psychiatry, the multi-patented, GRAS-affirmed, standardized Ashwagandha root and leaf extract,...

2014-06-28 08:21:00

- TAS-102 demonstrated a statistically significant improvement in overall survival and progression-free survival - BARCELONA, Spain and PRINCETON, N.J., June 28, 2014 /PRNewswire/ -- Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug. TAS-102 achieved statistically...

2014-06-23 08:27:43

Gelesis100 2.25 g demonstrated significant weight loss in a double-blind, placebo-controlled, parallel-group 12-week study of overweight and obese subjects, including prediabetics BOSTON, June 23, 2014 /PRNewswire/ -- Gelesis Inc., a company focused on developing treatments for overweight and obese subjects, including prediabetics, presented today the results of a proof of concept study with its lead product, Gelesis100. In the 12-week study, 2.25 g of Gelesis100 taken twice a day...

2014-06-17 08:30:10

MOMENCE, Ill., June 17, 2014 /PRNewswire/ -- FutureCeuticals, Inc. today announced publication of the results of another successful human clinical study on FruiteX-B® calcium fructoborate, a patented plant mineral complex. The double-blind, placebo-controlled study examined the effects of FruiteX-B® supplementation during fourteen days on subjects with self-reported knee discomfort. The study population was equally divided between generally healthy men and women ranging in ages...


Latest Bioethics Reference Libraries

OncoMouse
2013-10-02 09:29:43

The OncoMouse or Harvard Mouse is a type of laboratory mouse that has been genetically modified utilizing modification designed by Philip Leder and Timothy A. Stewart, of Harvard University, to carry a certain gene called an activated oncogene. The activated oncogene considerably increases the mouse’s vulnerability to cancer, therefore making the mouse suitable for cancer research. The rights to the invention were owned by DuPont until recently. The USPTO found that the patent expired in...

More Articles (1 articles) »
Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related